Literature DB >> 11276035

A flexible design for multiple armed screening trials.

D J Sargent1, R M Goldberg.   

Abstract

The goal of a screening trial is to examine several treatments with the intention of selecting one or more treatment(s) for further testing. Such a trial frequently occurs in the phase II setting, with the intention that the selected treatment be formally compared to a standard treatment in a phase III clinical trial. In this framework it is not essential that the very best treatment is definitely selected (such a decision would require a formal phase III trial), rather it is important that a substantially inferior treatment is not selected when a superior treatment exists. The level of evidence required to select a treatment based on this standard is lower than the evidence required to definitively order treatments. This paper introduces a flexible design for such trials, the flexibility coming from the use of a particular decision rule. The proposed rule states that if the observed difference in the success rates of the treatments is larger than some prespecified quantity d, then the treatment with the highest observed success rate is selected. However, if the observed difference is less than or equal to d, other factors may be considered in the selection. The goal of this design is to mirror clinical practice, where a treatment's success probability is often only one of many considerations in determining a treatment recommendation for a particular patient. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2001        PMID: 11276035     DOI: 10.1002/sim.704

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  22 in total

1.  Statistical methods for down-selection of treatment regimens based on multiple endpoints, with application to HIV vaccine trials.

Authors:  Ying Huang; Peter B Gilbert; Rong Fu; Holly Janes
Journal:  Biostatistics       Date:  2017-04-01       Impact factor: 5.899

2.  NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.

Authors:  Yaacov Richard Lawrence; Bhadrasain Vikram; James J Dignam; Arnab Chakravarti; Mitchell Machtay; Boris Freidlin; Naoko Takebe; Walter J Curran; Soren M Bentzen; Paul Okunieff; C Norman Coleman; Adam P Dicker
Journal:  J Natl Cancer Inst       Date:  2012-12-10       Impact factor: 13.506

3.  SMART Design Issues and the Consideration of Opposing Outcomes: Discussion of "Evaluation of Viable Dynamic Treatment Regimes in a Sequentially Randomized Trial of Advanced Prostate Cancer" by by Wang, Rotnitzky, Lin, Millikan, and Thall.

Authors:  Daniel Almirall; Daniel J Lizotte; Susan A Murphy
Journal:  J Am Stat Assoc       Date:  2012-04-27       Impact factor: 5.033

4.  Randomized phase II trials: time for a new era in clinical trial design.

Authors:  Sumithra J Mandrekar; Daniel J Sargent
Journal:  J Thorac Oncol       Date:  2010-07       Impact factor: 15.609

5.  Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study.

Authors:  C Kent Osborne; Patrick Neven; Luc Y Dirix; John R Mackey; Jean Robert; Craig Underhill; Rachel Schiff; Carolina Gutierrez; Ilenia Migliaccio; Valsamo K Anagnostou; David L Rimm; Patrick Magill; Mark Sellers
Journal:  Clin Cancer Res       Date:  2011-01-10       Impact factor: 12.531

6.  Lisinopril versus lisinopril and losartan for mild childhood IgA nephropathy: a randomized controlled trial (JSKDC01 study).

Authors:  Yuko Shima; Koichi Nakanishi; Mayumi Sako; Mari Saito-Oba; Yuko Hamasaki; Hiroshi Hataya; Masataka Honda; Koichi Kamei; Kenji Ishikura; Shuichi Ito; Hiroshi Kaito; Ryojiro Tanaka; Kandai Nozu; Hidefumi Nakamura; Yasuo Ohashi; Kazumoto Iijima; Norishige Yoshikawa
Journal:  Pediatr Nephrol       Date:  2018-10-03       Impact factor: 3.714

7.  Current issues in oncology drug development, with a focus on Phase II trials.

Authors:  Daniel J Sargent; Jeremy M G Taylor
Journal:  J Biopharm Stat       Date:  2009       Impact factor: 1.051

8.  Between-arm comparisons in randomized Phase II trials.

Authors:  Sin-Ho Jung; Stephen L George
Journal:  J Biopharm Stat       Date:  2009       Impact factor: 1.051

Review 9.  North Central Cancer Treatment Group--achievements and perspectives.

Authors:  Axel Grothey; Alex A Adjei; Steve R Alberts; Edith A Perez; Kurt A Jaeckle; Charles L Loprinzi; Daniel J Sargent; Jeff A Sloan; Jan C Buckner
Journal:  Semin Oncol       Date:  2008-10       Impact factor: 4.929

10.  Cyclosporine C2 monitoring for the treatment of frequently relapsing nephrotic syndrome in children: a multicenter randomized phase II trial.

Authors:  Kazumoto Iijima; Mayumi Sako; Mari Saito Oba; Shuichi Ito; Hiroshi Hataya; Ryojiro Tanaka; Yoko Ohwada; Koichi Kamei; Kenji Ishikura; Nahoko Yata; Kandai Nozu; Masataka Honda; Hidefumi Nakamura; Michio Nagata; Yasuo Ohashi; Koichi Nakanishi; Norishige Yoshikawa
Journal:  Clin J Am Soc Nephrol       Date:  2013-11-21       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.